WO2000031541A3 - Method of detecting neurofibromatosis type 1 - Google Patents

Method of detecting neurofibromatosis type 1 Download PDF

Info

Publication number
WO2000031541A3
WO2000031541A3 PCT/US1999/027292 US9927292W WO0031541A3 WO 2000031541 A3 WO2000031541 A3 WO 2000031541A3 US 9927292 W US9927292 W US 9927292W WO 0031541 A3 WO0031541 A3 WO 0031541A3
Authority
WO
WIPO (PCT)
Prior art keywords
neurofibromatosis type
detecting
midkine protein
disorder
mrna sequence
Prior art date
Application number
PCT/US1999/027292
Other languages
French (fr)
Other versions
WO2000031541A2 (en
Inventor
Andreas C Kurtz
Robert L Martuza
George A Mashour
Original Assignee
Univ Georgetown
Andreas C Kurtz
Robert L Martuza
George A Mashour
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown, Andreas C Kurtz, Robert L Martuza, George A Mashour filed Critical Univ Georgetown
Publication of WO2000031541A2 publication Critical patent/WO2000031541A2/en
Publication of WO2000031541A3 publication Critical patent/WO2000031541A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Neurofibromatosis type 1 disorders result in abnormal levels of midkine protein and/or the mRNA sequence encoding the midkine protein in the skin and/or blood serum of individuals having the disorder. Thus, test for abnormal levels of midkine protein and/or the mRNA sequence that encodes the midkine protein can be used to diagnose a neurofibromatosis type 1 disorder.
PCT/US1999/027292 1998-11-20 1999-11-18 Method of detecting neurofibromatosis type 1 WO2000031541A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10940498P 1998-11-20 1998-11-20
US60/109,404 1998-11-20

Publications (2)

Publication Number Publication Date
WO2000031541A2 WO2000031541A2 (en) 2000-06-02
WO2000031541A3 true WO2000031541A3 (en) 2000-09-08

Family

ID=22327478

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/027292 WO2000031541A2 (en) 1998-11-20 1999-11-18 Method of detecting neurofibromatosis type 1

Country Status (1)

Country Link
WO (1) WO2000031541A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1232826C (en) 1999-09-10 2005-12-21 村松乔 Early cancer tumor marker
DE102012020496A1 (en) 2012-10-18 2014-04-24 Charité - Universitätsmedizin Berlin Invitro diagnosis and/or early detection of neurofibromatosis type 1 and/or neurofibromatosis type 1-associated tumor from sample of a patient for treating the patient with the tumor, comprises detecting protein or its fragment in sample
EP2923203B1 (en) 2012-11-20 2018-10-03 The United States of America, as represented by The Secretary, Department of Health and Human Services Assay to measure midkine or pleiotrophin level for diagnosing a growth

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIOLOGICAL ABSTRACTS, Philadelphia PA USA; abstract no. PREV199799766263, abstract *
CHEMICAL ABSTRACTS, vol. 119, no. 23, 6 December 1993, Columbus, Ohio, US; abstract no. 242025, XP002136902 *
G.A. MASHOUR ET AL.: "Aberrant cutaneous expression of the angiogenic factor midkine is associated with neurofibromatosis type-1", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 113, no. 3, 1 September 1999 (1999-09-01), Washington DC USA, pages 398 - 402 *
G.A. MASHOUR ET AL.: "Midkine is differentially expressed in neurofibromin-deficient Schwann cells and human neurofibromas", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 23, no. 1-2, 25 October 1997 (1997-10-25), New Orleans, Louisiana, USA, pages 88 *
MEDLINE, Washington DC USA; abstract no. 99398478, abstract *
S. KIKUCHI ET AL.: "Midkine , a novel neurotrophic factor, promotes survival of mesencephalic neurons in culture", NEUROSCIENCE LETTERS, vol. 160, no. 1, 1993, Amsterdam NL, pages 9 - 12 *

Also Published As

Publication number Publication date
WO2000031541A2 (en) 2000-06-02

Similar Documents

Publication Publication Date Title
AU1634300A (en) System for use in footwear for measuring, analyzing, and reporting the performance of an athlete
WO2000000610A3 (en) Human signal peptide-containing proteins
ATE408422T1 (en) METHOD FOR INHIBITING IMMUNO-STIMULATORY RESPONSE ASSOCIATED WITH DNA
WO1995024650A3 (en) Methods of diagnosing and treating preeclampsia
WO2000021988A3 (en) Human ankyrin family protein
WO2000012711A3 (en) Human membrane channel proteins
WO2000018922A8 (en) Human carbohydrate-associated proteins
WO2000009709A3 (en) Proteases and associated proteins
SE9604815D0 (en) A method or diagnosis
WO2000026245A3 (en) Human membrane transport proteins
WO2000012703A3 (en) Protein transport-associated molecules
WO2001087142A3 (en) Method for determining fluctuation in functional state
WO2000014251A3 (en) Human transferase proteins
WO2000031541A3 (en) Method of detecting neurofibromatosis type 1
WO2003000844A3 (en) Protein modification and maintenance molecules
WO1999058558A3 (en) Cell signaling proteins
EP1291085A3 (en) Test strip compression element
WO1999061614A3 (en) Human socs proteins
WO2002002603A3 (en) Protein modification and maintenance molecules
WO2001088544A3 (en) Proteolytic enzymes in diagnosis of kidney disorders
ES541735A0 (en) METHOD FOR DETERMINING THE PRESSURE OF AN EVIL STATE IN TISSUES.
WO1999049037A3 (en) Protein phosphatase-related molecules
WO1998024896A3 (en) Muteins of obese protein
WO2000001821A3 (en) Neurotransmission associated proteins
WO2000015799A3 (en) Rna-associated proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase